A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis/Bladder Pain Syndrome
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Lidocaine (Primary)
- Indications Interstitial cystitis
- Focus Therapeutic Use
- Sponsors Allergan
- 06 Sep 2017 Status changed from active, no longer recruiting to completed.
- 17 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.